At the 2026 ASCO Annual Meeting, cannabinoid-based symptom management was recognized for its critical role in improving patient outcomes.
A major policy shift is reshaping how providers and payers approach symptom management. Here’s what cannabis rescheduling means for clinical care, reimbursement, and patient outcomes.
EO Care has appointed healthcare leaders William Fleming (former Humana executive) and Kristi Savacool (former Aon Hewitt CEO) to its Board of Directors, strengthening governance as cannabinoid-based symptom management enters mainstream healthcare.
The Administration’s decision to move to reclassify cannabis from Schedule I to Schedule III is a watershed moment for adult Americans who currently or might benefit from the responsible use of cannabinoids, especially oncology patients and older adults. It’s a long overdue step that will reduce stigma, open doors for essential research and product development, and increase access to care for patients.
As the leader in cannabinoid based symptom management for older adults, we applaud the Centers for Medicare & Medicaid Services (CMS) proposal to expand coverage for federally legal, hemp-derived cannabinoid-based products. At EO, we are uniquely positioned to meet the need of this new, covered cannabinoid care market.
At EO, we systematically track how patients feel and function after starting guided cannabis care. The data below come from real people using cannabis to manage symptoms such as pain, sleep disturbance, anxiety, and nausea/vomiting, under the guidance of our clinical protocols.
Meaningful improvements were reported by patients after one (1) week and sustained through four (4) weeks of guided cannabinoid care, particularly among people over 50 and cancer patients. Patients also reported low rates of use-limiting side effects with further reductions after receiving updated recommended product and/or dosing guidance via EO Care’s digital care platform.
New scalable, digital health offering makes personalized, clinically responsible cannabinoid guidance accessible to all older adults, adults in cancer treatment and cancer survivors.The platform was designed and tested with patients and clinicians at leading hospitals and NCI-Designated Cancer Centers.
Cancer Support Community (CSC) has teamed up with EO Care, a leader in clinically guided cannabis health solutions, to provide cancer patients, survivors, and their caregivers with comprehensive support.
Recently, the Department of Health and Human Services recommended that cannabis be reclassified from a Schedule I Controlled Substance to a Schedule III Controlled Substance under the federal Controlled Substances Act. In a PM360 article Rescheduling Cannabis to a Schedule III Controlled Substance: A Regulator’s Perspective,
As more states legalize the use of cannabis, it can be challenging for employers to keep up and find reliable information. A recent Benefits Pro article, Employees are more likely to apply for jobs that offer cannabis benefits, shares findings from an EO Care ...
1 in 2 people will get cancer in their lifetime, and 40% of cancer patients use cannabis for treatment of symptoms. But clinical guidance for cannabis is difficult to find. That’s why Imerman Angels is partnering with EO Care — the first clinically guided cannabis health and wellness solution for employers, payers, and associations — to provide cannabis care and advice to members. ImermanAngels.org visitors will be able to access educational content including whether cannabis is right for them, how to optimize use, and even how to reduce use.
Ethan Zohn truly embodies the word “survivor.” In 2001, he won Survivor Africa, the third season of the popular reality TV show — and later became a two-time survivor of a rare blood cancer. At the age of 35 and in the prime of his life, this fit, former professional soccer player was diagnosed with CD20+ Hodgkin’s Lymphoma. Over several years, Ethan endured aggressive treatment including two stem cell transplants.
40% of cancer patients use cannabis to help the treatment of symptoms. But many are going it alone without clinical guidance, which can be ineffective and even unsafe. That’s why non-profit cancer survivor and caregiver support community Twist Out Cancer is partnering with EO Care...
EBN Talks with Bill Van Faasen, former chairman and CEO of Blue Cross Blue Shield Massachusetts and EO Care board member
On August 30, 2023, after a scientific/clinical review the US Department of Health and Human Services (HHS) acknowledged that cannabis has medicinal uses and recommended rescheduling cannabis to a Class 3 drug
In a recent Benefits Pro article What employers need to know about "guided use" of cannabis by Dr. Brooke Worster, an Associate Professor of Medicine at Jefferson Health in Philadelphia, PA, the Director of the Division of Supportive Oncology, and the Program Director of Cannabis Medicine for the Science and Business Master’s Program...
As employers continue to navigate the evolving dynamics of employee cannabis use, Human Resource Executive spoke with Dr. Brooke Worster, an Associate Professor of Medicine at Jefferson Health in Philadelphia, PA, the Director of the Division of Supportive Oncology...
eo Care in partnership with HR.com hosted an Employee Cannabis Use – Prevalence, Implications & Solutions webinar for HR professionals where we reviewed the prevalence of cannabis being at an all-time high, the risks of unguided use, and the benefits of employers offering health & wellness support in the form of clinically guided essential cannabis guidance for critical illnesses such as cancer, as well as symptom support, such as pain management, anxiety, and sleeplessness; resulting in improved workforce health, job satisfaction, and increased productivity.
BOSTON, Aug. 17, 2022 (GLOBE NEWSWIRE) -- EO Care, Inc. ("EO" or "The Company"), a digital health company focused on cannabinoid-based treatments, announced the launch of a new, HIPAA-compliant service and technology platform to meet the need for scalable, affordable, data-informed cannabis care with ongoing clinical oversight.
In 2018, my father was diagnosed with stage IV bladder cancer. Anyone with a loved one who has received a cancer diagnosis understands how the world instantly flips on its head. In the weeks following Dad’s diagnosis, our lives all totally changed. One priority overtook all others: easing Dad’s pain. Opioids were fraught with side effects, so we turned to cannabis.
Cannabis is illegal in the United States, but there are two dispensaries in my town. Cannabis is legal in my state, but I can’t consume it in public or bring it one state over.
Chronic pain is prevalent. A 2016 report estimates that over 20% of adults in the United States have experienced some form of chronic pain. Of those 50 million Americans, 8% suffer from some form of high impact chronic pain; pain that has lasted over three months and prohibits them from performing important activities in their daily lives.
People are suffering. Cannabis offers the potential of relief, but cannabis care today leaves much to be desired in the way of guidance, data, and consistency. eo is a digital therapeutic, telemedicine platform and clinical data source. We are on a mission to deliver the future of cannabis care through personalized, calendar-based care plans and ongoing clinical guidance delivered on an intuitive digital platform.
Not all patients are the same. Each person has unique underlying health conditions, personal experiences, and needs. What works for one patient is not guaranteed to work for all. Some patients might be allergic to a specific medication, others might be able to tolerate it but are unable to take it due to incompatible work schedules, and others might be a perfect fit for the same medication.
Last week, you took an edible to help manage your anxiety after a long work day. The cannabis provided some relief, but since then you haven’t been able to recreate that result. Starting your cannabis journey is daunting, and it can be hard to know where to go for guidance.
Proponents of cannabis use in a medical context have often suggested that it is a superior substitute of opioid for chronic pain management. Cannabis owes its analgesic properties to components called cannabinoids, with the two most prominent being cannabidiol (CBD) and tetrahydrocannabinol (THC). Both compounds have similar potential for treating chronic pain, however, while THC is addictive, CBD is not and therefore is of special clinical interest.
If you are having trouble getting a good night’s sleep these days, you’re not alone. Up to 70 million people are affected by sleep disorders, according to data from the National Institutes of Health, and consumers are spending $70 billion a year on sleep aids, 65% of which goes to medications.
Researchers have recently analyzed popular vaping behavior and revealed the advantages of vaporizing medical cannabis. The general advantages of vaporizing medical cannabis include portability, concealability, and efficiency, while the medical advantages like promoting tobacco cessation and it’s quick-acting effects.
Along with THC, the cannabis plant produces over 400 different chemical compounds that include dozens of other cannabinoids like CBD and CBN, and hundreds terpenes like pinene, linalool and myrcene. When the compounds are applied together (whether it’s through smoking, vaping or especially transdermal applications), they work to provide unique effects and benefits.
Get special offers, event invites and the latest on new care offerings and product releases.
Wise Use for All
© 2026 All rights reserved. Patents pending. EO Care, Inc.
